AvenCell
Developer of T cell-based immunotherapies intended to support cancer treatment. The company focuses on building chimeric antigen receptor T cells for precise targeting of cancer antigens to overcome t...
Valuation
$227M
Latest known
Share Price
N/A
Total Raised
$177.8M
Last Round
N/A